Impaired cognition and Alzheimer’s disease (AD) may first manifest with distinctive metabolic dysfunctions beginning decades prior to disease manifestation. Disease classification methods primarily investigate structural and functional connectivity patterns of brain regions, requiring complex neuroimaging. Metabolomic markers are currently being investigated as they may provide early insight into patients at high risk for AD or impaired cognition.1, 2
Where are your Clinical Trials?
It has proven to be difficult, if not impossible, to proceed to full-scale randomized controlled trials (RCTs) for most of the natural methods that cannot be patented or otherwise monopolized.










0 Comments